ImmunityBio stock gained premarket after founder Patrick Soon-Shiong highlighted early immune activation data for Anktiva, showing increased lymphocyte levels. The drug was also added to Macau's drug list and updated NCCN guidelines. These developments helped IBRX rise over 5% this week, reversing a two-week losing streak.